Peptide Critic Community

@Randy I'm about 2 months into my cycle CJC [no dac] +P. The dosage I picked up goes .3MG x3 per day on workout days, once on non-workout days. Seeing good results out of it.

@Randy It’s funny; a friend of mine is on reta and like it a lot but is increasing his dose because of food noise/hunger. I use tirz and he keeps trying to get me to move to reta but I am not having trouble with food noise on a very low dose. Hence why I always say to take it slow and see what works best for you. Maybe I will try reta at some point, but right now I see no reason to mess with variables that aren’t causing problems.

@lancerlot23 Any update on how this went? Researching Reta and Im +10 bpm, with the same negative results you mention. Last thing i need is more BPM's!

@hammertime65 Found this on Penguin. Will try Tesa test using a couple of vials at discount, plus a vile. 30% OFF + FREE Peptide per $150 spend – code: RESEARCH30

Very little talk of the accelerating tissue repair aspect. Has anyone else experimented with different sites specifically for that? I've found the back of the shoulders, beside the kneecap [inner and outer] to be great. Above the kneecap and elbow not so much. I've also noticed that if feels better to hit a joint the night before working out on it, instead of the night you did. This is with 2.5mg dosage: 50mg-10mL for 2, 25unit injections.

For research use only. Not medical advice. Overview Mazdutide (LY3437943) is a dual GLP-1/glucagon agonist similar to survodutide but generally smoother and more tolerable, with a softer glucagon hit and less aggressive appetite suppression. Typical weekly exploration ranges from 2–10 mg, with gradual escalation over 8–12 weeks. It has good synergy with GLP-1/GIP agonists (e.g., tirzepatide) and is commonly used in “Ghetto Reta” stacks due to its cleaner side-effect profile. Weekly Titration Schedule Weeks 1–2: Intro Phase Dose: 2 mg once weekly Purpose: Establish baseline tolerability and assess GI sensitivity. Notes: This is a gentle entry point compared to survodutide’s 0.6 mg start. Weeks 3–4: Light Phase Dose: 4 mg once weekly Produces noticeable appetite reduction but usually without overwhelming gastric slowing. Hold at 2 mg longer if nausea persists. Weeks 5–6: Moderate Phase Dose: 6 mg once weekly This is the working dose for many research subjects. Represents a good balance of efficacy and tolerability. Weeks 7–8: Strong Phase Dose: 8 mg once weekly Strong metabolic effects emerge here. Suitable for subjects who tolerated 6 mg without significant GI burden. Weeks 9–12: Upper-Tier Phase Dose: 10 mg once weekly This is the practical “top end” for most research setups. Only escalate to 10 mg after several weeks of stability at 8 mg. Maintenance Dosing (Week 13+) Standard Maintenance 6–8 mg once weekly Best balance for long-term tolerability. High-End Maintenance 10 mg once weekly Used when the goal is more aggressive metabolic impact or retatrutide-like synergy in stacks. Frequency & Timing Once weekly, same day each week. Delayed GI effects can occur (Day 2–3), especially at ≥6 mg. When stacking with tirzepatide, escalations should be slower than this standalone schedule. Cycle Length Titration requires 8–12 weeks depending on sensitivity. Full research cycles often run 16–48 weeks, typically maintaining 6–10 mg. Common Research Notes Mazdutide is smoother and less nausea-inducing compared to survodutide. Appetite suppression is strong but less abrupt subjects often describe it as “cleaner” or “more natural.” When stacked with tirzepatide, GI effects compound; many researchers cap mazdutide at 4–6 mg in combination protocols.

For research use only. Not medical advice. Overview Survodutide is a dual GLP-1/glucagon receptor agonist typically researched in the 0.6–6 mg weekly range, with gradual escalation over 10–12 weeks. It produces strong appetite suppression and a pronounced metabolic effect due to its glucagon activity — much more aggressive than standard GLP-1 compounds. Slow titration is essential for GI tolerability. Weekly Titration Schedule Weeks 1–2: Intro Phase Dose: 0.6 mg once weekly Purpose: Allow subjects to adapt to GLP-1 + GC stimulation. Notes: Even this low dose can feel strong for GLP-1-naive subjects. Weeks 3–4: Light Phase Dose: 1.2 mg once weekly Appetite suppression increases significantly here. Hold longer at 0.6 mg if nausea or fullness is excessive. Weeks 5–6: Moderate Phase Dose: 1.8 mg once weekly Represents a comfortable mid-range dose for many subjects. Escalate only if prior doses were well tolerated. Weeks 7–8: Strong Phase Dose: 2.4 mg once weekly This dose often produces robust metabolic effects without overwhelming tolerability. Many researchers remain here for multiple weeks before proceeding. Weeks 9–10: High Phase Dose: 3.6 mg once weekly Strong GC-driven thermogenic activity emerges. If subjects struggle at this point, step back to 2.4 mg until stable. Weeks 11–12: Upper-Tier Phase Dose: 4.8 mg once weekly This was near the top end of phase 2 obesity trial dosing. GI and appetite suppression effects intensify; titrate cautiously. Week 13+ Maintenance Two research-validated maintenance ranges: Standard Maintenance 4.8 mg once weekly Provides excellent efficacy with manageable tolerability. Maximum Maintenance 6.0 mg once weekly Represents the high end used in some modeling and extended research runs. Move to 6.0 mg only after 4.8 mg is fully tolerated for several weeks. Frequency & Timing Once weekly at a consistent time. Due to the glucagon component, many subjects experience delayed nausea (Day 2–3). Avoid rushing escalations — Survodutide hits harder per mg than typical GLP-1s. Cycle Length Titration requires 10–12 weeks minimum. Full research cycles typically last 20–48 weeks depending on goals and maintenance dose. Common Research Notes Survodutide is significantly stronger milligram-for-milligram than semaglutide or tirzepatide due to dual receptor activation. GI load increases steeply with each escalation — slow progression improves tolerability. When used in stacks (e.g., tirz + survo “Ghetto Reta”), researchers often cap survo at 0.6–1.5 mg because synergy multiplies the effect.

I posted on a discord server that my food nose was back since I started survo. Tirz had me completely dead to appetite. Some "expert" jumped on and explained the mechanisms of why survo would not cause hunger/food noise. Well, I know what I have experienced. But luckily it has died down and only lasts the day I take the survo. But I've been eating keto/carnivore ish most of the time so sugar cravings aren't a thing for me. I'd rather have a large pepperoni pizza. I am now down 78 pounds since January so I'm sticking with this combo.

Have you tried other GLP's from vendors like Nextchems Retatrutide?

Question regarding reconstituting this one. I hear AA is needed to keep the pH low due to potentially getting amyloid fibrils. What is the proper way? I have never used anything but Hospira BAC water. I will not be researching this but the wife wants to so I am trying to set her up with it. Can anyone give me some help on this?

Weekly uptake for my rat is as follows. .3mg, .6mg, 1mg, 2mg, 3mg, 4mg, 5mg, will be administering 6mg today. Around week 5 and on, my test subject would get really bad abdominal pain followed by more than usual bowl movement around 1-2 days before the scheduled next dose. Also, increase fiber for those who are susceptible to constipation like my subject. You are welcome. We use chia seeds soaked in water over night. Work your way up to a full dose. 8mg, 10mg, 14mg etc. See about the effects before starting Reta. But yeah, just what we’ve been doing here. Not actual advise. Also, be sure to keep up with essential vitamins like A for your eye sight. Fat soluble so take with fat. And so forth since a lot of vitamin and mineral consumption by your test subject will be at a higher rate. And that plus less food intake, recomndation is to provide nutrient dense food to your subject. Any how, hope this helps.

@diegoc He did not bring any receipts...Not that I am protecting TB but putting him down like that and then making it appear that you are sending links that show all that you said, which they are not, is WEAK at best. If you are going to say someone is a fake and has insurance fraud etc etc then show those receipts and don't just regurgitate what you may have heard or read...It makes you look small and petty. Just my .02

Discussion thread for the blog post on PeptideCritic.com. Read the article: HYB’s 10mg “Retatrutide” Disaster: When Your Telegram Plug Sells You a Mystery Peptide Share your thoughts, ask questions, or continue the conversation below!

test

I think Elon would love GLPs in Mars… keep ppl lean and only eating the necessary foods

Probably a dumb question but that link prompts me to login to staging.peptidecritic.com Is this normal?

@WowwyZowwy i put the naughty banner on their vendor page with a link to @saltyalty post

Discussion thread for the blog post on PeptideCritic.com. Read the article: Introducing the Finest 3D-Printed Vial Carrying Cases Share your thoughts, ask questions, or continue the conversation below!